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1. Introduction 
Venous thromboembolism (VTE) manifesting as deep vein thrombosis(DVT) or 
pulmonary embolism (PE), is one of the most common complications of hospitalization 
and is associated with short and long-term morbidity, mortality and resource 
expenditure.  Routine use of thromboprophylaxis reduces adverse patient outcomes while 
at the same time decreasing overall costs. Almost all hospitalized patients have at least 




Trauma (major trauma or lower-extremity injury) 
Immobility, lower-extremity paresis 
Cancer (active or occult) 
Cancer therapy (hormonal, chemotherapy, angiogenesis inhibitors, radiotherapy) 
Venous compression (tumor, hematoma, arterial abnormality)  
Previous VTE  
Increasing age 
Pregnancy and the postpartum period  
Estrogen -containing oral contraceptives or hormone replacement therapy 
Selective estrogen receptor modulators  
Erythropoiesis-stimulating agents  
Acute medical illness  
Inflammatory bowel disease  
Nephrotic syndrome  
Myeloproliferative disorder  
Paroxysmal nocturnal hemoglobinuria 
Obesity 
Central venous catheterization  
Inherited or acquired thrombophilia 
Table 1. Risk Factors for VTE  
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Without thromboprophylaxis, the incidence of objectively confirmed, hospital-acquired 
DVT is approximately 10 to 40% among medical or general surgical patients and 40 to 60% 
following major orthopedic surgery (Table 2)(1-2). 
 
Patient Group  DVT Prevalence, % 
Medical patients 10-20 
General, surgery 15-40 
Major gynecologic surgery 15-40 
Major Urologic surgery 15-40 
Neurosurgery 15-40 
Stroke 20-50 
Flip or knee arthroplasty, HFS 40-60 
Major trauma 60-80 
SCI 60-80 
Critical care patients 10-80 
* Rates based on objective diagnostic: screening for asymptomatic DVT in patients not receiving 
thromboprophylaxis.  
Table 2. Approximate Risk of DVT in Hospitalized Patients  
Several hundred clinical trials of thromboprophylaxis, conducted over the past 50 years, 
have shown that the use of prophylaxis reduces the rates of deep vein thrombosis (DVT), 
proximal DVT, pulmonary embolism (PE), and fatal PE by more than 60% in a broad 
spectrum of hospitalized patients with a very low risk of adverse effects. Although effective 
strategies for the prevention of venous thromboembolism (VTE) are widely available and 
existence of several guidelines for individual risk assessments to determine thrombosis risk 
and prophylaxis, a significant number of patients still develop VTE because appropriate 
thromboprophylaxis is not correctly prescribed. Adapting evidence-based practice 
guidelines into existing local policies and protocols has been shown to significantly increase 
the proportion of at-risk patients receiving appropriate thromboprophylaxis. 
The American College of Chest Physicians (ACCP) sponsor and publish what are generally 
considered to be the most comprehensive and most commonly utilized of these 
guidelines(3). A summary of the 2008 ACCP Guidelines on the Prevention of VTE is 
presented in Table 3, (4). 
The type and duration of surgery clearly influence the risk of DVT. Numerous efforts have 
been made to identify the patients most at risk for DVT and PE. The studies of this problem 
categorize risk levels as low, medium, high, and very high.  
Patients at low risk are under 40 years of age contemplating minor surgery and with no 
associated risk factors. The incidence of DVT is less than 2%, proximal DVT 0.4%, PE at 0.2%, 
and fatal PE 0.02%. This group requires no special prophylaxis other than early ambulation.  
Patients at moderate risk are those aged 40–50 who are undergoing major surgery, have no 
associated risk factors, and expect a prompt recovery. The frequency of DVT is 10%–20% 
proximal DVT, 2%–4%, clinical PE 1%–2%, and fatal PE 0%– 1.4%. This group will benefit 
from prophylactic treatment with LMWH, or LDUH and ES. 
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Patient groups Recommended 
thromboprophylaxis 
options* 
Optimal duration of 
prophylaxis 
Low VTE Risk: 
Medical - fully mobile, 
brief admission, no 
additional risk factors 
 Surgical - procedure < 
30 minutes, patient 
mobile, no additional risk 
factors 
 
Moderate VTE Risk: 
Acute medical illness 
Major general surgery 
Major gynecologic 





High VTE Risk: 
Hip or knee arthroplasty 





High VTE Risk: 
Major trauma, (including 




High bleeding risk 
No prophylaxis 











Combinations of a 





Rivaroxaban or dabigatran 





heparin Combinations of a 
mechanical method and an 
anticoagulant 
 
Mechanical method of 
prophylaxis (GCS, PCD, VFP) 
Consider anticoagulant 












Continue until discharge 
for the majority of patients. 







Minimum of 10 days and 





Continue until discharge 
for the majority of patients. 
Prophylaxis should be 
continued for the inpatient 
rehabilitation period. 
 
Duration appropriate for 
the specific patient risk 
group. 
 
GCS indicates graduated compression stocking; PCD, pneumatic compression device, VFP, venous foot 
pump. 
Table 3. Risk stratification, recommended thromboprophylaxis and optimal duration of 
prophylaxis by patient group. 
The high-risk group are patients over 60, candidates for major surgery, with associated risk 
factors. The prevalence of DVT is 20%–40%; proximal DVT 4%–8%, clinical PE 2%–4% and 
fatal PE 0.4%–1%. Higher doses of LMWH or LDUH should be used, together with 1 PC 
devices and ES.  
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In the very-high-risk group of patients with major trauma (multiorgan, spinal, pelvic, long 
bone fractures), intermittent compression devices and ES should be started as early as 
possible, and LMWH or LDUH initiated as soon as it is safe. In cases of major trauma, with 
absolute contraindications for anticoagulants, the prophylactic indication of an inferior vena 
cava (IVC) filter should be considered, especially in cases with duplex ultrasonography 
demonstration of DVT. 
2. Mechanical methods of thromboprophylaxis and the role of combined 
thromboprophylaxis modalities 
Early and frequent mobilizitation of hospitalized patients at risk for VTE is an important 
part of patient care. However, many patients cannot be fully ambulatory early after  
surgery. Furthermore, the majority of hospital-associated, symptomatic thromboembolic 
events occur after patients have started to ambulate, and mobilization alone does not 
provide adequate thromboprophylaxis for hospital patients. Specific mechanical methods of 
thromboprophylaxis, which include graduated compression stockings (GCS), intermittent 
pneumatic compression (IPC) devices, and the venous foot pump (VFP), increase venous 
outflow and/or reduce stasis within the leg veins. Use of mechanical thromboprophylaxis is 
the preferred option for patients at high risk for bleeding. If the high bleeding risk is 
temporary, consideration should be given to starting pharmacologic thromboprophylaxis 
once this risk has decreased. Mechanical thromboprophylaxis may also be considered in 
combination with anticoagulant thromboprophylaxis to improve efficacy in patient groups 
for which this additive effect has been demonstrated(3,5,6). However, since they are not 
associated with bleeding, and some methods have demonstrated efficacy as DVT prevention 
in clinical trials, the use of mechanical prophylaxis in combination with pharmacological 
prophylaxis may be helpful in certain situations. For example, in major trauma patients who 
have a high risk of bleeding at presentation (as after head injury), we use mechanical 
prophylaxis initially followed by anticoagulant prophylaxis with LMWH when safe (5,6). 
This strategy could be adopted in any postoperative situation in which the initial risk of 
bleeding is high.  
3. VTE in cancer patients 
The association of cancer with thrombosis has been known for more than 100 years. Since 
the beginning it was regarded as a 2-way association, first cancer increases the risk of 
thrombosis(as first observed by Armand Trousseau in 1865), and secondy clotting activation 
increases the progression of cancer(as postulated by Billroth in 1878). Patients with cancer 
have at least a sixfold-increased risk of VTE compared to those without cancer and active 
cancer accounts for almost 20% of all new VTE events occurring in the community. 
Furthermore, VTE is one of the most common and costly complications seen in cancer 
patients. Although the association between cancer and thrombosis has been known for 
years, there is now an increasing recognition among cancer providers of the impact of 
thrombotic complications on patients with cancer (7,8). Several factors have contributed to 
this heightened awareness. Firstly, cancer-associated VTE is increasingly prevalent. In a 
recent analysis of more than 1 million hospitalized patients with cancer, the rate of VTE 
increased by 28% from 1995 to 2003 (P < .0001)(9). Secondly, the consequences of VTE are 
better understood. Thrombosis is the second-leading cause of death in patients with cancer 
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and is associated with worsened mortality (10-12). In addition, patients with cancer who 
suffer VTE have an increased risk of recurrent VTE, bleeding complications, morbidity, and 
utilization of health care resources(13,14). Finally, newer anticancer agents particularly 
antiangiogenic drugs, appear to be more thrombogenic than conventional chemotherapy 
(15,16). Selected cancer patients with established VTE will need extended treatment to 
prevent its recurrence. In addition, a number of new cancer therapies have been associated 
with a further increase in the risk of VTE, warranting primary prophylaxis. Given the high 
mortality rate for VTE in cancer patients, it is imperative to ensure that all health-care 
professionals become familiar with and utilize the latest guidelines and tools for timely and 
evidence-based risk assessment, prevention, and treatment of VTE(17,18). 
A hypercoagulable state or low-grade DIC is common in patients with cancer. The results of 
laboratory tests indicate that a process of fibrin formation and removal is ongoing during 
the development of malignancy. Reported rates of venous thromboembolism (VTE) in 
patients with cancer range from 4% to 31%(19,23). Cancer alone elevates the risk of 
thrombosis 4-fold; chemotherapy increases the risk 6.5-fold(24,25). Patients who undergo 
cancer surgery have a higher risk of postoperative VTE than those who have surgery for a 
nonmalignant disease (26). VTE is the second leading cause of death in cancer patients, and 
the presence of VTE in patients with cancer has been reported to increase the likelihood of 
death by 2- to 8-fold (27-32). 
Results of the FRONTLINE (Fundamental Research in Oncology and Thrombosis) survey 
underscored the need for development of clinical guidelines focusing on VTE in cancer 
patients: surgeons and medical oncologists reported that they used VTE prophylaxis in only 
about 50% and 5% of their patients, respectively(33). Two sets of guidelines devoted 
specifically to oncology patients are available to help guide clinicians: recommendations by 
the American Society of Clinical Oncology (ASCO) and by the National Comprehensive 
Cancer Network (NCCN) (34-35). Both sets of recommendations direct that all adults 
hospitalized with cancer receive prophylactic anticoagulation therapy in the absence of 
contraindications. However, a recent review of more than 70,000 hospitalized patients with 
cancer in whom an indication for thromboprophylaxis had been identified showed that the 
rate of appropriate prophylaxis was only 27%(36). 
Alcalay et al. was found VTE as a significant predictor of death within 1 year of colorectal 
cancer diagnosis, among the patients with local or regional stage disease, but not among the 
patients with metastatic disease(37). 
Thromboembolic events are a major cause of morbidity and mortality in patients 
undergoing surgery. Cancer patients requiring curative abdominal surgery are considered 
to be at a particularly high risk for VTE, and thromboprophylaxis is strongly recommended 
(38). Studies of Western populations have shown that DVT rates range from 15% to 30% for 
cancer patients not receiving thromboembolic prophylaxis, and a meta-analysis by Colditz 
et al. estimated fatal PE rates of 0.1%–0.8% (39,40). Colorectal surgery is associated with a 
specific high risk of postoperative thromboembolic complications relative to other general 
surgery (41-43). The incidences of DVT and PE in colorectal cancer surgery patients who do 
not receive thromboembolic prophylaxis are approximately 40% and 5%, respectively (42-
43). Moreover, late VTE rates of 10%– 20% have been reported in patients who received 
LMWH thromboprophylaxis in the first postoperative week (44). 
The randomized double-blind ENOXACAN II study, and the multicenter randomized 
Denmark/Norway study found that thromboprophylaxis for 4 weeks after abdominal or 
pelvic cancer surgery reduced the incidence of venographically demonstrated asymptomatic 
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thrombosis (45-46). In those studies, the rate of asymptomatic thrombosis was 5%–7% after 
prolonged prophylaxis. Although the majority of asymptomatic DVT is not clinically 
significant, there is an association between asymptomatic DVT and the subsequent 
development of symptomatic VTE (47). In most studies, the ratio of asymptomatic DVT to 
symptomatic VTE ranges from 5:1 to 10:1. If a ratio of 10:1 is applied, the incidence of 
symptomatic DVT is approximately 0.5%–0.7% after prolonged thromboprophylaxis (4 
weeks), similar to that found in the present study (0.63%). It shows the comparable 
incidence with that of Western countries, although in the present study thromboprophylaxis 
was administered only to high-risk patients and the treatment was of much shorter duration 
(median 3 days) and at a lower dose than that reported in those other studies. 
Venous thromboembolism is a common complication in cancer patients due to the 
hypercoagulable state induced by changes in the coagulation system (48). A prothrombotic 
state is present in many cancer patients as a result of an increase in procoagulants, such as 
tissue factor, cancer procoagulant, and factor VIIa, and hypercoaguability increases as the 
cancer progresses (49,50). Patients with metastatic cancers are at an increased risk of VTE. 
Several studies have shown a direct association between cancer stage and thrombosis risk. 
Recent studies showed that a higher initial cancer stage was a strong independent risk factor 
for developing VTE within the first year after diagnosis of cancer (51). In the Korean study, 
multivariate analysis showed metastatic colorectal cancer (stage IV) was found a predictor 
of VTE. Moreover, advanced colorectal cancer (stage III, IV) was also a predictor of VTE, 
and patients with advanced cancer were twice as likely to be diagnosed with VTE as 
patients with less-advanced cancer (52). 
4. Anticoagulant use in renal insufficiency 
Renal clearance is the primary mode of elimination for several anticoagulants, including 
LMWH, fondaparinux, and the new oral factor Xa and Ha inhibitors. Therefore, with 
reduced renal function, these drugs may accumulate and may increase the risk of bleeding, 
particularly in elderly patients and those at high risk for bleeding (53). The relationship 
between renal impairment and drug accumulation for the various LMWHs appears to be 
variable and may be related to the chain length distribution of the different LMWH 
preparations (54). Two recent studies in hospitalized patients, the majority of whom were 
critically ill and had creatinine clearances less than 30 mL/min, have shown no 
bioaccumulation of dalteparin 5000 U once daily based on serial anti-factor Xa levels (55,56). 
Therefore, we do not reduce the prophylaxis dose of dalteparin in patients with renal 
insufficiency. In patients receiving intermittent hemodialy-sis, we suggest that the LMWH 
be administered after the dialysis session. With enoxaparin thromboprophylaxis, we suggest 
that 30 mg once daily be used. We also suggest that fondaparinux, rivaroxaban and 
dabigatran be avoided unless future evidence demonstrates that these agents can be used 
safely in patients with severe renal insufficiency. 
5. Concomitant use of regional anesthesia techniques and anticoagulant 
prophylaxis  
Neuraxial blockade (spinal or epidural anesthesia and continuous epidural analgesia) 
results in a significant reduction in cardiopulmonary morbidity compared with general 
anesthesia and narcotic-based systemic analgesia, as well as better pain control and patient 
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satisfaction (57). However, concerns have been raised about a possible increased risk of 
epidural or spinal hematoma and spinal cord ischemia or paraplegia with use of 
concomitant anticoagulant prophylaxis (58,59).We believe that anticoagulant 
thromboprophylaxis with LMWH or LDH can safely be given along with neuraxial 
blockade with proper patient selection and timing of doses. Further details can be found in 
Section 1.5 of the 8th ACCP Prevention of VTE guidelines(3). In summary: 
1. Neuraxial blockade should be avoided in patients with systemic bleeding disorders and 
if hemostasis is impaired by an anticoagulant. The spinal needle or epidural catheter 
should be inserted at a time when there is minimal or no anticoagulant effect present. 
2. Anticoagulant prophylaxis should be delayed if a hemorrhagic aspirate ("bloody tap") is 
encountered during initial needle or catheter placement. 
3. Removal of an epidural catheter should be done when the anticoagulant effect is at a 
minimum (usually just before the next scheduled injection) and anticoagulant 
prophylaxis should be delayed for at least 2 hours after spinal needle or epidural 
catheter removal. 
4. In patients with an indwelling epidural catheter, we suggest that warfarin be avoided 
altogether or that the catheter be removed less than 48 hours after starting warfarin 
because of its unpredictable anticoagulant effect. 
5. The safety of continuous epidural analgesia with concomitant administration of 
fondaparinux or one of the new oral anticoagulants is not known and this combination 
is best avoided at this time. 
6. Patients with epidural catheters who are given anticoagulant thromboprophylaxis 
should be carefully monitored for symptoms and signs of spinal cord compression. If 
spinal hematoma is suspected, diagnostic imaging and surgical decompression should 
be performed rapidly to reduce the risk of permanent spinal cord damage. 
7. Every hospital using neuraxial blockade along with anticoagulant prophylaxis should 
develop a written protocol. 
8. For patients receiving deep peripheral nerve blocks along with anticoagulant 
prophylaxis, it is reasonable to use the same cautions described above. 
6. Trauma 
Deep venous thrombosis DVT and pulmonary embolism are among the most common 
preventable sources of mortality and morbidity in trauma patients treated in intensive care 
units. In various studies, DVT and PE have been demonstrated to range from 6%to 40% and 
from2%to 22%, respectively, in patients with serious spinal/head trauma (5, 6, 60-62). 
Knudson et al. and Geerts et al. reported that in trauma patients other than the ones with 
head trauma LMWH was better than unfractionated heparin for DVT prophylaxis (61,62). 
Vanek, with a metaanalysis, showed that intermittent pneumatic compression (IPC) 
decreased the relative risk of DVT by 62%, 47%, and 48% compared to placebo, high-
pressure stockings, and LMWH, respectively (63). Norwood et al. reported that enoxaparin 
for DVT prophylaxis in patients with acute brain injury having an Abbreviated Injury Score 
of >  3 did not increase the morbidity (64). Early use of LMWH for DVT prophylaxis in the 
presence of intraabdominal solid organ injury (liver, spleen, kidney) may also be safe (6, 61). 
A properly placed and managed intermittent pneumatic compression device could provide 
thromboprophylaxis of comparable efficacy to that of LMWH, in patients with moderate 
and severe injury (65). 
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7. Laparoscopic surgery 
The expanding use of laparoscopy last 3 decades has profoundly changed surgical diagnosis 
and therapy. However there is still some controversy over the best practice for prevention of 
deep vein thrombosis (DVT) during laparoscopic surgery. There is considerable uncertainty 
related to the thromboembolic risk after laparoscopic procedures, and the use of 
thromboprophylaxis is controversial. Surgical trauma is generally less with laparoscopic 
than with open abdominal surgery, but activation of the coagulation system is similar to or 
only slightly less with laparoscopic procedures. Laparoscopic operations may be associated 
with longer surgical times than comparable open procedures. Both pneumoperitoneum and 
the reverse Trendelenburg position reduce venous return from the legs, creating venous 
stasis. Patients undergoing laparoscopic procedures may have shorter hospital stays, but 
they may not mobilize more rapidly at home than those who have had open procedures. 
Despite the paucity of evidence, the European Association for Endoscopic Surgery has 
recom mended that intraoperative IPC be used for all prolonged laparoscopic procedures 
(66). In 2006, the Society of American Gastrointestinal Endoscopic Surgeons recommended 
the use of similar thromboprophylaxis options for laparoscopic procedures as for the 
equivalent open surgical procedures (67). However, available evidence does not support a 
recommendation for the routine use of thromboprophylaxis in these patients (68,69,70).  
Furthermore, with anticoagulant thromboprophylaxis, the risk of major bleeding may 
exceed the rate of thrombotic complications(71). Patients who are at particularly high 
thromboembolic risk can be considered for thromboprophylaxis with any of the modalities 
currently recommended for surgical patients (3,72). 
8. Treatment of VTE 
Treatment for VTE has been widely studied, and treatment guidelines have been published 
and frequently updated by the American College of Chest Physicians (ACCP), American 
College of Emergency Physicians, Eastern Association for the Surgery of Trauma, and 
Institute for Clinical Systems Improvement(1,3). Generally, acute treatment consists of low-
molecular-weight heparin (LMWH) or unfractionated heparin (UFH) for 4 to 5 days, with 
overlapping therapy to warfarin until an international normalized ratio (INR) of  >2 for two 
consecutive days is achieved. Anticoagulation should be continued for at least 3 to 12 
months, depending on the site of thrombosis and risk factors. Failure to provide adequate 
VTE treatment can result in patient morbidity and mortality, with a substantial economic 
burden(73). Although the evidence and consensus strongly favor LMWH treatment for up 
to 6 months in patients with cancer with established VTE, evidence is lacking to support 
continuing treatment beyond 6 months. It is likely that anticoagulation can be safely 
discontinued in certain patients (eg, patients who developed a VTE while on adjuvant 
chemotherapy and are in complete remission withnoplans for further treatment). 
Conversely, certain patients will continue to be at risk for recurrent VTE (eg, a patient with 
cancer with metastatic disease with plans for indefinite chemotherapy). Data from well-
designed randomized clinical trials are essential for clinicians to make evidencebased 
recommendations in these varied settings.  
Activation of the hemostatic system promotes tumor growth, angiogenesis, and metastasis. 
Antithrombotic agents could therefore potentially influence tumor biology and outcomes in 
patients with cancer.  Multiple recent studies have evaluated the effect of anticoagulants on 
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survival, with encouraging but inconclusive results (74). Given that anticoagulant 
prophylaxis could have dual benefits for patients with cancer reducing VTE and prolonging 
survival it is vital to pursue well-designed clinical trials of thromboprophylaxis focusing on 
survival(75). 
9. Appendix 
An informative summary from American College of Chest Physicians Evidence-Based 
Clinical Practice Prevention of Venous Thromboembolism Guidelines (8th Edition)(3). 
10. Guyatt grading(76) 
Grade 1 recommendations are strong and indicate that the benefits do or do not outweigh 
risks, burden, and costs. 
Grade 2 suggestions imply that individual patient values may lead to different choices  
11. General surgery 
- For low-risk general surgery patients who are undergoing minor procedures and have 
no additional thromboembolic risk factors, ACCP recommend against the use of 
specific thromboprophylaxis other than early and frequent ambulation (Grade 1A). 
- For moderate-risk general surgery patients who are undergoing a major procedure for 
benign disease, patients should receive thromboprophylaxis with LMWH, LDUH, or 
fondaparinux (each Grade 1A). 
- For higher-risk general surgery patients who are undergoing a major procedure for 
cancer, patient should receive thromboprophylaxis with LMWH, LDUH three times 
daily, or fondaparinux (each Grade 1A). 
- For general surgery patients with multiple risk factors for VTE who are thought to be at 
particularly high risk, AACP recommend that a pharmacologic method (ie,   LMWH,  
LDUH three times daily, or fondaparinux)  be combined with the optimal use of a 
mechanical method (te, graduated compression stockings [GCS] and/or IPC) [Grade 1C]. 
- For general surgery patients with a high risk of bleeding, optimal use of mechanical 
thromboprophylaxis with properly fitted GCS or IPC is best method (Grade 1A). When 
the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- For patients undergoing major general surgical procedures, we recommend  that 
thromboprophylaxis continue  until  discharge from hospital (Grade 1A). For selected 
high-risk general surgery patients, including some of those who have undergone major 
cancer surgery or have previously had VTE, ACCP suggest that continuing 
thromboprophylaxis after hospital discharge with LMWH for up to 28 days be 
considered (Grade 2A). 
12. Cancer patients 
- For cancer patients undergoing surgical procedures, ACCP recommend routine 
thromboprophylaxis that is appropriate for the type of surgery (Grade 1A). Refer to the 
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recommendations in the relevant surgical subsections. 7.0.2. For cancer patients who are 
bedridden with an acute medical illness, ACCP recommend routine 
thromboprophylaxis as for other high-risk medical patients (Grade 1A). Refer to the 
recommendations in Section 6.0. 7.0.3. For cancer patients with indwelling central 
venous catheters, ACCP recommend that clinicians  not use  either prophylactic doses  
of LMWH (Grade IB), or minidose warfarin (Grade IB) to try to prevent catheter-related 
thrombosis. 
- For cancer patients receiving chemotherapy or hormonal therapy, ACCP recommend 
against the routine use of thromboprophylaxis for the primary prevention of VTE 
(Grade 1C). 7.0.5. For cancer patients, ACCP recommend against the routine use of 
primary thromboprophylaxis to try to improve survival (Grade IB). 
13. Laparoscopic surgery 
- For patients undergoing entirely laparoscopic procedures who do not have additional 
thromboembolic risk factors, routine use of thromboprophylaxis is unneccessary. Early 
and frequent ambulation should be forced (Grade 1B). 
- For patients undergoing laparoscopic procedures in whom additional VTE risk factors 
are present, ACCP recommend the use of thromboprophylaxis with one or more of 
LMWH, LDUH, fondaparinux, IPC, or GCS (all Grade 1C). 
14. Trauma 
- For all major trauma patients, ACCP recommend routine thromboprophylaxis if 
possible (Grade 1A). 
- For major trauma patients, in the absence of a major contraindication, ACCP 
recommend that clinicians use LMWH thromboprophylaxis starting as soon as it is 
considered safe to do so (Grade 1A). An acceptable alternative is the combination of 
LMWH and the optimal use of a mechanical  method of thromboprophylaxis (Grade 
IB). 
- For major trauma patients, if LMWH thromboprophylaxis is contraindicated due to 
active bleeding or high risk for clinically important bleeding, we recommend that 
mechanical thromboprophylaxis with IPC or possibly with GCS alone be used (Grade 
IB). When the high bleeding risk decreases, we recommend that pharmacologic 
thromboprophylaxis be substituted for or added to the mechanical thromboprophylaxis 
(Grade 1C). 
- In trauma patients, ACCP recommend against routine DUS screening for asymptomatic 
deep vein thrombosis (DVT) (Grade IB). We do recommend DUS screening in patients 
who are at high risk for VTE (eg, in the presence of a spinal cord injury [SCI], lower-
extremity or pelvic fracture, or major head injury), and who have received suboptimal 
thromboprophylaxis or no thromboprophylaxis (Grade 1C). 
- For trauma patients, ACCP recommend against the use of an inferior vena cava (IVC) 
filter as thromboprophylaxis (Grade 1C). 
- For major trauma patients, ACCP recommend the continuation of thromboprophylaxis 
until hospital discharge  (Grade 1C). For trauma patients with impaired mobility who 
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undergo inpatient rehabilitation, ACCP suggest continuing thromboprophylaxis with 
LMWH or a VKA (target INK, 2.5; range, 2.0 to 3.0) (Grade 2C). 
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